KR20210143906A - 리포솜 제제, 및 이의 사용 및 제조 방법 - Google Patents

리포솜 제제, 및 이의 사용 및 제조 방법 Download PDF

Info

Publication number
KR20210143906A
KR20210143906A KR1020217035257A KR20217035257A KR20210143906A KR 20210143906 A KR20210143906 A KR 20210143906A KR 1020217035257 A KR1020217035257 A KR 1020217035257A KR 20217035257 A KR20217035257 A KR 20217035257A KR 20210143906 A KR20210143906 A KR 20210143906A
Authority
KR
South Korea
Prior art keywords
mole
composition
phospholipid
salt
phosphorylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217035257A
Other languages
English (en)
Korean (ko)
Inventor
아그네스 라팔코
뎃페이 시라쿠라
사무엘 에릭 그린버그
Original Assignee
글라이코민 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글라이코민 인코포레이티드 filed Critical 글라이코민 인코포레이티드
Publication of KR20210143906A publication Critical patent/KR20210143906A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217035257A 2019-03-29 2020-03-27 리포솜 제제, 및 이의 사용 및 제조 방법 Pending KR20210143906A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826874P 2019-03-29 2019-03-29
US62/826,874 2019-03-29
PCT/US2020/025246 WO2020205530A1 (en) 2019-03-29 2020-03-27 Liposomal formulations, and methods of using and preparing thereof

Publications (1)

Publication Number Publication Date
KR20210143906A true KR20210143906A (ko) 2021-11-29

Family

ID=72666933

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217035257A Pending KR20210143906A (ko) 2019-03-29 2020-03-27 리포솜 제제, 및 이의 사용 및 제조 방법

Country Status (19)

Country Link
US (1) US12691131B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946365A4 (cg-RX-API-DMAC7.html)
JP (1) JP7583741B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210143906A (cg-RX-API-DMAC7.html)
CN (1) CN113873998A (cg-RX-API-DMAC7.html)
AR (1) AR119705A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020252005B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019593A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134828A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002512A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014274A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192663A1 (cg-RX-API-DMAC7.html)
IL (1) IL286713B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021011876A (cg-RX-API-DMAC7.html)
PE (1) PE20212366A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552428A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110623PA (cg-RX-API-DMAC7.html)
TW (1) TWI906214B (cg-RX-API-DMAC7.html)
WO (1) WO2020205530A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021011876A (es) 2019-03-29 2022-01-04 Glycomine Inc Formulaciones liposomicas y metodos de uso y preparacion de las mismas.
US20250248939A1 (en) * 2022-04-18 2025-08-07 City Of Hope Lipid nanoparticles, nucleic acids, and methods of use
TW202543582A (zh) * 2024-02-29 2025-11-16 美商葛里柯麥公司 脂質體調配物及其使用及製備方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
WO2000051565A1 (en) 1999-03-02 2000-09-08 The Liposome Company, Inc. Encapsulation of bioactive complexes in liposomes
US7060291B1 (en) * 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
US7011845B2 (en) 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
HUP0303616A3 (en) 2001-03-26 2006-07-28 Alza Corp Mountain View Liposome composition for improved intracellular delivery of a therapeutic agent
CA2471960A1 (en) 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient liposomal encapsulation
EP1478341A4 (en) 2002-01-09 2009-05-20 Transave Inc EFFICIENT ENCAPSULATION OF NUCLEIC ACIDS IN MEDIUM SIZE LIPOSOMES
WO2004103510A2 (en) 2003-05-14 2004-12-02 The Regents Of The University Of Colorado Methods and apparatus using electrostatic atomization to form liquid vesicles
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
JP2008518925A (ja) 2004-10-29 2008-06-05 ネオファーム、インコーポレイティッド リポソーム製剤の製造プロセス
FR2897779B1 (fr) 2006-02-24 2009-04-17 Orphan Europ Sarl Manossyl-1 phosphates, procede de preparation et utilisation en therapeutique, notamment vis-a-vis dy syndrome cdg-la
KR20100127842A (ko) 2008-03-26 2010-12-06 유니버시티 오브 옥스퍼드 소포체 표적화 리포좀
CA2761916A1 (fr) * 2009-05-14 2010-11-18 Sanofi Pasteur Procede pour adjuver le lipopolysaccharide (lps) des bacteries a gram-negatif
WO2010138550A1 (en) 2009-05-27 2010-12-02 Northeastern University Conjugated nanodelivery vehicles
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
US20110257233A1 (en) 2010-03-19 2011-10-20 Sanford-Burnham Medical Research Institute Benzoisothiazolones as inhibitors of phosphomannose isomerase
EP2598120B1 (en) 2010-07-31 2018-09-05 The Scripps Research Institute Compositions and methods for inducing immune tolerance
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
HK1206644A1 (en) 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Lipid-derived neutral nanoparticles
WO2014063757A1 (en) 2012-10-26 2014-05-01 Universiteit Leiden Delivery methods
CN104884637A (zh) 2012-11-05 2015-09-02 普隆奈治疗公司 利用生物标志物通过bcl2表达的调节治疗癌症的方法
ES3026657T3 (en) 2013-09-16 2025-06-11 Glycomine Inc Pharmaceutical preparation of carbohydrates for therapeutic use
US20150132369A1 (en) 2013-11-09 2015-05-14 Exir Nano Sina Company Nanoliposomal cyclosorin formulations for immunosuppresion and methods for the production thereof
CN107207614B (zh) 2014-10-09 2022-01-11 利普泰克有限公司 嵌合蛋白
US20170165374A1 (en) 2015-11-18 2017-06-15 Insmed, Inc. Compositions and methods for treating bacterial infections
MX2021011876A (es) 2019-03-29 2022-01-04 Glycomine Inc Formulaciones liposomicas y metodos de uso y preparacion de las mismas.

Also Published As

Publication number Publication date
TWI906214B (zh) 2025-12-01
EA202192663A1 (ru) 2022-03-01
JP2022527638A (ja) 2022-06-02
IL286713B2 (en) 2025-07-01
SG11202110623PA (en) 2021-10-28
AU2020252005B2 (en) 2025-11-27
US12691131B2 (en) 2026-07-28
CN113873998A (zh) 2021-12-31
PH12021552428A1 (en) 2022-07-11
EP3946365A4 (en) 2023-04-19
AR119705A1 (es) 2022-01-05
CL2021002512A1 (es) 2023-01-06
IL286713A (en) 2021-10-31
IL286713B1 (en) 2025-03-01
PE20212366A1 (es) 2021-12-21
TW202102231A (zh) 2021-01-16
JP7583741B2 (ja) 2024-11-14
EP3946365A1 (en) 2022-02-09
BR112021019593A2 (pt) 2021-12-14
US20220184107A1 (en) 2022-06-16
AU2020252005A1 (en) 2021-11-04
WO2020205530A1 (en) 2020-10-08
CA3134828A1 (en) 2020-10-08
CO2021014274A2 (es) 2022-01-17
MX2021011876A (es) 2022-01-04

Similar Documents

Publication Publication Date Title
JP7395693B2 (ja) 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
US20240390514A1 (en) Polyglutamated antifolates and uses thereof
EP2323693B1 (en) Drug carriers
AU603860B2 (en) Liposomes with enhanced circulation time
US20240082155A1 (en) Pharmaceutical preparation of carbohydrates for therapeutic use
JP7583741B2 (ja) リポソーム製剤、ならびにリポソーム製剤を使用および調製する方法
EP2680822B1 (en) Vesicle compositions
EP0298280A2 (en) Animal derived cell with antigenic protein introduced therein
US8241663B2 (en) Liposome preparation
EA050120B1 (ru) Липосомальные фармацевтические композиции и способ их применения
AU2003280761B2 (en) Liposome
EP4108251A1 (en) Griffithsin for use in a method of preventing or treating infections with respiratory viruses
TW202600145A (zh) 治療患有先天性醣基化障礙(cdg)的個體的先天性醣基化障礙和共濟失調的方法
CN1679957B (zh) 含脂质体的癌症治疗用药物组合物
Arnold Systemic delivery of peptides and macromolecules in nasal formulations containing an alkylglycoside

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902